11030-86-7

Basic information

• Product Name: (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
• CAS NO: 11030-86-7
• Molecular Formula: C₁₂H₂₅N₃O₇
• Molecular Weight: 323.3428
• Mol File: 11030-86-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 593.6°C at 760 mmHg
• Flash Point: 312.8°C
• Density: 1.56g/cm³
• Vapor Pressure: 1.46E-16mmHg at 25°C
• Refractive Index: 1.651
• CAS DataBase Reference: (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside(11030-86-7)
• EPA Substance Registry System: (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside(11030-86-7)

Safety Data

• Hazardous Substances Data: 11030-86-7(Hazardous Substances Data)

Upstream product

• 7205-49-4 paromomycin sulfate 
• 2037-48-1 2-deoxystreptamine 
• 7542-37-2 paromomycin 
• 6128-39-8 paromomycin hydrochloride 
• 935871-52-6 2'-N-acetyl-paromamine 
• 236115-74-5 4-O-(2-azido-2-deoxy-3,4,6-tri-O-benzyl-α-D-glucopyranosyl)-2-deoxystreptamine 
• 236115-61-0 [(1S,2S,3R,4S,6R)-2-acetoxy-4,6-diazido-3-hydroxy-cyclohexyl] acetate 
• 236115-65-4 2-azido-2-deoxy-3,4,6-tri-O-benzyl-1-phenylthio-β-D-glucopyranoside 
• 166516-67-2 phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside 
• 90899-14-2 (1α,2β,3α,4β,6β)-4,6-Diazido-1,2,3-cyclohexantriol 
• 90852-19-0 (1α,2β,3α,4β,6β)-4,6-Diazido-1,2,3-cyclohexantriol-triacetat 

Downstream Products

• 88897-25-0 1-N-3',4',5,6-tetra-O-benzoyl-6'-O-tertbutyldimethylsilyl-1,3,2'-tri-N-p-tolylsulfonylparomamine 
• 88897-24-9 6'-O-tertbutyldimethylsilyl-1,3,2'-tri-N-p-tolylsulfonylparomamine 

Relevant articles and documents

The chemistry of the gentamicins. I. Characterization and gross structure of gentamicin A.

-

Novel aminoglycosides and uses thereof in the treatment of genetic disorders

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low cytotoxicity and selectivity towards eukaryotic cells are provided. Also provided are processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.